Having trouble accessing articles? Reset your cache.

Astellas adds new focus area via $3B takeout of gene therapy company Audentes

Astellas announced late Monday that it would add genetic regulation as an R&D focus through the acquisition of Audentes for $60 per share, about $3 billion, in cash.

It

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE